by ComplianceQuest

Inspection Tracker

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

FDA Guidance Global Templates

Start with a Free ConsultationBook 30 minutes with a ComplianceQuest specialist.Book a Call

Sign In Create a Free Account

Big News: FDA is moving from MasterControl to ComplianceQuest.See Why

Search AgentQ/

Talk to a Specialist

Loading…

My DashboardInspection TrackerWarning LettersAmgen Inc.

All Warning Letters

Amgen Inc.

Warning LetterOpen

Recipient Title Chairman and Chief Executive Officer, 1 Amgen Center Dr. Thousand Oaks , CA 91320 United StatesIssued Aug 12, 2026The Office of Prescription Drug Promotion (OPDP)

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations1

Issue DateAug 12, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: Amgen Inc.
Location: Recipient Title Chairman and Chief Executive Officer, 1 Amgen Center Dr. Thousand Oaks , CA 91320 United States
FEI Number: N/A
Country: United States
Issue Date: August 12, 2026
Issuing Office: The Office of Prescription Drug Promotion (OPDP)
Product Type: Drugs
Status: Open

Subject

Drug Product/Misbranded, False & Misleading Claims

Amgen Inc. FDA Warning Letter, August 12, 2026